Therapeutic drug monitoring of HIV protease inhibitors using high-performance liquid chromatography with ultraviolet or photodiode array detection

Therapeutic Drug Monitoring

Volumn 23, Issue 6, 2001, Pages 679-688

  Leibenguth, P ^a   Le Guellec, C ^a   Besnier, J M ^a   Bastides, F ^a   Mace M ^a   Gaudet, M L ^a   Autret Leca, E ^a   Paintaud, G ^a  

^a UNIVERSITÉ DE TOURS   (France)

Author keywords

Drug monitoring; High pressure liquid chromatography; HIV protease inhibitor

Indexed keywords

AMPRENAVIR; BROMAZEPAM; CARBAMAZEPINE; CLORAZEPATE; DEXTROPROPOXYPHENE; DIDANOSINE; HYDROXYITRACONAZOLE; INDINAVIR; ITRACONAZOLE; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PARACETAMOL; PROTEINASE INHIBITOR; PYRIMETHAMINE; RIFABUTIN; RITONAVIR; SAQUINAVIR; STAVUDINE; SULFAMETHOXAZOLE; TRIMETHOPRIM; ZIDOVUDINE; ZOLPIDEM;

ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; SIDE EFFECT; STANDARD; TREATMENT FAILURE; ULTRAVIOLET RADIATION; ULTRAVIOLET SPECTROPHOTOMETRY;

AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DRUG MONITORING; HIV PROTEASE INHIBITORS; HUMANS; MIXED FUNCTION OXYGENASES; SENSITIVITY AND SPECIFICITY;

EID: 0035177672     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200112000-00015     Document Type: Article

References (48)

1. Clinical pharmacology of HIV protease inhibitors: Focus on saquinavir, indinavir and ritonavir
2. Antiretroval therapy for HIV infection in 1998: Updated recommendations of the international AIDS Society-USA Panel
3. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection
4. Indinavir concentrations and antiviral effect
5. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy
6. Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients
7. Exposure-response relationships for saquinavir, zidovudine and zalcitabine in combination therapy
8. Indinavir pharmacokinetics and pharmacodynamics in children with human immunodeficiency virus infection
9. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1 infected patients on indinavir-containing triple therapy
10. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics
11. Pharmacologic considerations for therapeutic success with antiretroviral agents
12. Ordered accumulation of mutations in HIV-protease confers resistance to ritonavir
13. Therapeutic drug monitoring of antiretrovirals in human immunodeficiency virus infection
14. Determination of ritonavir, a new HIV protease inhibitor, in biologic samples using reversedphase high-performance liquid chromatography
15. Highperformance liquid chromatographic determination of ritonavir in human plasma, cerebrospinal fluid and saliva
16. Determination of indinavir, a HIV-1 protease inhibitor, in human plasma using ionpair reversed-phase high-performance liquid chromatography
17. Rapid quantification of indinavir in human plasma by high-performance liquid chromatogaphy with ultraviolet detection
18. Determination of saquinavir in human plasma by high-performance liquid chromatography
19. High-performance liquid chromatographic method for determination of nelfinavir a novel HIV-1 protease inhibitor, in human plasma
20. Simultaneous determination of ritonavir and saquinavir, two human immunodeficiency virus protease inhibitors, in human plasma by high-performance liquid chromatography
21. Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversedphase high-performance liquid chromatography
22. Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion pair high-performance liquid chromatography with ultraviolet detection
23. Simultaneous determination of five HIV-protease inhibitors: Amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by solidphase extraction and column liquid chromatography
24. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies
25. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDRI and MRPI but retain antiviral efficacy in cell lines expressing these transporters
26. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein
27. Effects of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: Evidence of cytochrome P-450 A and P-glycoprotein induction
28. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery
29. Protease inhibitors as inhibitors of human cytochromes P450: High risk associated with ritonavir
30. Drug interactions of HIV Protease inhibitors
31. Pharmacokinetic variability and strategy for therapeutic drug monitoring of saquinavir in HIV-1 infected individuals
32. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with HIV-I
33. A comparison of BID and TID dosing of nelfinavir mesylate when given in combination with stavudine and lamivudine for up to 48 weeks
34. High-dose nevirapine: Safety, pharmacokinetics and antiviral effect in patients with HIV infection
35. Population pharmacokinetics of efavirenz in phase II studies and relationship with efficacy
36. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus
37. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers
38. Concentration-controlled antiretroviral therapy
39. Therapeutic drug monitoring of nelfinavir 1250 bid in treatment-naive patients improves therapeutic outcome after 1 year: Results from ATHENA
40. Therapeutic drug monitoring of indinavir in treatment-naive patients improves therapeutic outcome after 1 year: Results from ATHENA
41. The role of therapeutic drug monitoring in treatment of HIV infection
42. A short-term study of safety, pharmacokinetics and efficacy of ritonavir, an inhibitor of HIV-1 protease
43. Ritonavir and saquinavir combination therapy for the treatment of HIV infection
44. Pharmacokinetic variability and strategy for therapeutic drug monitoring of saquinavir in HIV-1 infected individuals
45. Indinavir can be taken with regular meals when administerd with ritonavir
46. Single- and multiple-dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease
47. Nelfinavir concentrations in HIV-infected patients treated with tid or bid regimen
48. Combination therapy with amprenavir, abacavir and efavirenz in HIV-infected patients failing a protease-inhibitor regimen: Pharmacokinetic drug interactions and antiviral activity